2023-03-31 00:49:09 ET
- Aprea Therapeutics press release ( NASDAQ: APRE ): Q4 GAAP EPS of -$0.92 beats by $2.30 .
- As of December 31, 2022, the Company reported cash and cash equivalents of $28.8 million compared to $53.1 million as of December 31, 2021. The Company believes its cash and cash equivalents as of December 31, 2022, combined with the gross proceeds received from the Company’s $5.5 million public offering of common stock in February 2023 will be sufficient to meet its current projected operating requirements into the third quarter of 2024.
For further details see:
Aprea Therapeutics GAAP EPS of -$0.92 beats by $2.30